Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories


Omega transcends to collect $85m
Omega Therapeutics is firing up preclinical development of an epigenomic drug platform invented at Whitehead Institute and incubated by Flagship Pioneering.
Nura Bio navigates $73m series A
Nura Bio is working on neuroprotective treatments that exploit discoveries made at OHSU and UT Southwestern.
Indigo Diabetes stabilises $44.5m
Indigo Diabetes increased its total funding to $52.6m with a series B round backed by Imec.xpand and returning investor Qbic.
Forge Biologics computes $40m series A
Forge is working on a gene therapy treatment invented at UPMC but has covered its bases by targeting viral vector production for third-party clients.
Scalable Capital mounts $58m series D campaign
Scalable Capital is valued in excess of $460m following a round that lifted the digital wealth manager's total funding to about $130m.
Dexterity has a knack for funding
Dexterity, a logistics robot spinout of Stanford, has emerged from stealth with series A funding and debt financing from Stanford-StartX Fund.
Cerevance captures $65m series B
UPMC Enterprises has contributed to a $20m series B extension for Cerevance, which is commercialising Rockefeller University research.
Spin Memory executes extra series B cash
NYU-founded Spin Memory has now raised $60.3m in series B capital, having lured the return of Allied Minds, Arm and Applied Ventures.

Other News

Glympse Bio gleans series B funding
Section 32 has led a $46.7m series B round that will support further development of the MIT spinout's biosensor-based diagnostics device.
Paige pings investors for extra series B cash
Memorial Sloan Kettering spinout Paige’s series B total stands at $70m following a third tranche featuring Goldman Sachs and Healthcare Venture Partners.
Nine Square sides with ATP for $50m series A
UCSF has unveiled Nine Square Therapeutics with $50m in series A capital from founding investor Apple Tree Partners.
Evidation Health generates $45m results
McKesson Ventures came onboard for the health data provider Evidation's series D round, helping it hike its overall funding to $106m five years after being co-founded by Stanford Health Care.
XSky stores $45.3m series D
Cloud storage provider XSky pushed its funding haul to $38m after securing the return of a Tsinghua University's fund management affiliate.
Bolt latches onto $93.5m series C
Novo, Pfizer and Nan Fung helped provide $93.5m for the Stanford immunotherapy spinout as it advances its lead asset towards the clinic.

Editor's Picks

Big deal: Oxford PV begins capturing series D
Goldwind, Legal & General and Equinor have all taken part in a series D that achieved a $41m first close and boosted the Oxford spinout’s total equity and debt to more than $118m.
Big deal: Ribon ties together $65m series B
Ribon Therapeutics has emerged out of stealth after three years of developing a lead asset targeting cancer based on research at MIT, UT Southwestern and Harvard Medical School.
Big deal: NMD flexes series A muscles
Aarhus University spinout NMD Pharma, which focuses on therapies for neuromuscular conditions, has attracted the support of several corporates for its $47m series A round.
Big deal: Touchstone helps inject $73m into Cell Medica
Touchstone Innovations, which co-founded the cellular immunotherapy developer in 2007, has contributed to another funding round.
test reg